Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin for myocardial salvage in STEMI undergoing primary PCI
2014-001205-41Phase 3Terminated
- Sponsor
- Sociedade Portuguesa de Cardiologia
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute ST-segment elevation myocardial infarction (STEMI) and myocardial infarction (MI) comparing Vildagliptin plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Myocardial salvage at 3 months. Started Oct 2014; status: terminated.
02
Drugs
vildagliptin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)myocardial infarction (MI)
Beyond the preview
Go deeper on 2014-001205-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001205-41.